NRG-GU009 / RGUP21002 / PREDICT-RT / Kevin Bylund
Basic Study Information
Purpose:
This phase III trial compares less intense hormone therapy and radiation therapy to
usual hormone therapy and radiation therapy in treating patients with high risk prostate
cancer and low gene risk score. This trial also compares more intense hormone therapy
and radiation therapy to usual hormone therapy and radiation therapy in patients with
high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate
cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses
high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy
treatment may work the same at controlling prostate cancer compared to the usual 24
month hormone therapy treatment in patients with low gene risk score. Adding apalutamide
to the usual treatment may increase the length of time without prostate cancer spreading
as compared to the usual treatment in patients with high gene risk score.
Location: Highland Hospital
Lead Researcher (Principal Investigator)
Lead Researcher:
Kevin Bylund
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search